Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease

Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 59(6), P. 494 - 503

Published: April 4, 2024

Language: Английский

---

The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 2, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading chronic worldwide, with alarming prevalence reaching epidemic proportions.

Language: Английский

---

Effects of the triglyceride-glucose index on non-alcoholic fatty liver disease: causal evidence from longitudinal cohort studies

Archives of Gerontology and Geriatrics, Journal Year: 2025, Volume and Issue: 133, P. 105813 - 105813

Published: March 4, 2025

Language: Английский

---

Global burden and future trends of metabolic dysfunction-associated steatotic liver disease: 1990-2021 to 2045

Annals of Hepatology, Journal Year: 2025, Volume and Issue: unknown, P. 101898 - 101898

Published: March 1, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly non-alcoholic fatty disease, is a growing global health challenge. This study examines the burden of MASLD from 1990 to 2021 and projects data for 2045. Using Global Burden Disease (GBD) Study 2021, analyzed across 204 countries focusing on prevalence, incidence, deaths, disability-adjusted life years (DALYs). Linear Joinpoint regression assessed trends, an age-period-cohort model evaluated outcomes, Bayesian forecasted future cases. In approximately 1.27 billion people globally had MASLD, with higher prevalence in males (51.41%). There were 48.35 million new cases, primarily (52.24%). The age-standardized rate (ASPR) increased 12,085.09 15,018.07 per 100,000 (AAPC 0.71). incidence (ASIR) rose 475.54 593.28 caused 138,328 females experiencing mortality (52.18%). East Asia, South North Africa/Middle highest rates, while Western Europe showed fastest growth. By 2045, ASIR projected reach 928.10 100,000, resulting 667.58 predominantly affecting males. poses significant notable gender regional disparities. increase by 2045 underscores need urgent public interventions targeted strategies mitigate this epidemic.

Language: Английский

---

Significant Dose-Response Association of Physical Activity and Diet Quality With Mortality in Adults With Suspected NAFLD in a Population Study

The American Journal of Gastroenterology, Journal Year: 2023, Volume and Issue: 118(9), P. 1576 - 1591

Published: Feb. 16, 2023

INTRODUCTION: We aimed to determine whether higher levels (volume and intensity) of physical activity (PA) diet quality (DQ) are associated with better survival rates in nonalcoholic fatty liver disease (NAFLD). METHODS: Using data from the 2011–2014 National Health Nutrition Examination Survey, 3,548 participants a Fatty Liver Index ≥60 were included. PA was collected using wrist-worn triaxial accelerometer expressed as 2 metrics Monitor-Independent Movement Summary (MIMS) units: average daily MIMS, which represents volume, peak 30-minute is highest 30 MIMS min/d intensity. DQ assessed by Healthy Eating Index-2015. Mortality follow-up recorded Death linkage through December 31, 2019. RESULTS: Our analyses revealed dose-dependent, nonlinear association all-cause mortality linear mortality. The maximum protective dose volume observed at 14,300 MIMS/min (adj. HR: 0.20, 95% CI: 0.11–0.38). intensity 54.25 0.10, 0.05–0.23), beyond risks flattened. Index-2015 showed its effect 66.17 0.54, 0.40–0.74). Higher lower risk cardiovascular-related but not cancer-related A healthier linked reduced cardiovascular-specific cancer-specific Sensitivity that beneficial effects on remained significant across sex, racial/ethnic, age groups well without NAFLD. DISCUSSION: findings suggest accumulated effort cardiovascular US adults NAFLD

Language: Английский

---

Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(5), P. 4583 - 4583

Published: Feb. 26, 2023

Nonalcoholic fatty liver disease (NAFLD), a chronic condition associated with metabolic dysfunction and obesity, has reached epidemic proportions worldwide. Although early NAFLD can be treated lifestyle changes, the treatment of advanced pathology, such as nonalcoholic steatohepatitis (NASH), remains challenge. There are currently no FDA-approved drugs for NAFLD. Fibroblast growth factors (FGFs) play essential roles in lipid carbohydrate metabolism have recently emerged promising therapeutic agents diseases. Among them, endocrine members (FGF19 FGF21) classical (FGF1 FGF4) key regulators energy metabolism. FGF-based therapies shown benefits patients NAFLD, substantial progress been made clinical trials. These FGF analogs effective alleviating steatosis, inflammation, fibrosis. In this review, we describe biology four metabolism-related FGFs (FGF19, FGF21, FGF1, their basic action mechanisms, then summarize recent advances biopharmaceutical development

Language: Английский

---

Precision Medicine in Fatty Liver Disease/Non-Alcoholic Fatty Liver Disease

Journal of Personalized Medicine, Journal Year: 2023, Volume and Issue: 13(5), P. 830 - 830

Published: May 14, 2023

Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic disease, and related to fatal non-fatal liver, metabolic, cardiovascular complications. Its non-invasive diagnosis effective treatment remain an unmet clinical need. NAFLD a heterogeneous that commonly present in context of metabolic syndrome obesity, but not uncommonly, may also be without abnormalities subjects with normal body mass index. Therefore, more specific pathophysiology-based subcategorization (FLD) needed better understand, diagnose, treat patients FLD. A precision medicine approach for FLD expected improve patient care, decrease long-term outcomes, develop better-targeted, treatments. We herein based on our recently proposed subcategorization, which includes metabolic-associated (MAFLD) (i.e., obesity-associated (OAFLD), sarcopenia-associated (SAFLD, lipodystrophy-associated (LAFLD)), genetics-associated (GAFLD), multiple/unknown causes (XAFLD), combined (CAFLD) as well advanced stage fibrotic (FAFLD) end-stage (ESFLD) subcategories. These other advances, whole, are enable only improved quality life, considerable reduction healthcare system costs associated FLD, along options treatments near future.

Language: Английский

---

Review and expert opinion on MAFLD, oxidative stress and multifunctional management

Drugs in Context, Journal Year: 2024, Volume and Issue: 13, P. 1 - 11

Published: Jan. 9, 2024

Metabolic-associated fatty-liver disease (MAFLD), previously known as non-alcoholic fatty liver disease, is the most widespread and emerging chronic worldwide, with increasing prevalence rates also in Asia-Pacific region. The has a high socio-economic burden it negatively impacts finances quality of life individuals affected major on healthcare systems. important pathological event MAFLD aetiopathogenesis oxidative stress, which leads to functional structural abnormalities well being involved development other concomitant cardiometabolic diseases. rather complex multisystemic clinical condition involving damage wide spectrum extrahepatic manifestations such obesity, type 2 diabetes, metabolic syndrome cardiovascular This complexity requires cooperation multiple experts identify at an early stage, treat associated comorbidities, promptly refer patient hepatologist when needed. review summarizes current knowledge about reports opinion group southeast Asia region, journey patients developing countries, role stress antioxidant treatment, importance multidisciplinary approach for diagnosis management. article part

Language: Английский

---

Global Epidemiological Impact of PNPLA3 I148M on Liver Disease

Liver International, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 7, 2024

ABSTRACT The prevalence of metabolic dysfunction‐associated steatotic liver disease (MASLD) has increased exponentially over the past three decades, in parallel with global rise obesity and type 2 diabetes. It is currently most common cause liver‐related morbidity mortality. Although been identified as a key factor MASLD, individual differences susceptibility are significantly influenced by genetic factors. PNPLA3 I148M (rs738409 C>G) variant greatest impact on risk developing progressive MASLD likely other forms disease. This prevalent across globe, allele (G) frequency exhibiting considerable variation. Here, we review contribution to burden regional prevalence, focusing recent evidence emerging from population‐based sequencing studies assessments. We calculated population attributable fraction (PAF) means quantifying MASLD. Furthermore, employ quantitative trait locus (QTL) analysis ascertain associations between rs738409 range phenotypic traits. suggests that these QTLs may underpin pleiotropic effects extrahepatic Finally, outline potential avenues for further research identify areas investigation future studies.

Language: Английский

---

Cross talk between the liver microbiome and epigenome in patients with metabolic dysfunction-associated steatotic liver disease

EBioMedicine, Journal Year: 2024, Volume and Issue: 101, P. 104996 - 104996

Published: Feb. 5, 2024

The pathogenesis of MASLD (metabolic dysfunction-associated steatotic liver disease), including its severe clinical forms, involves complex processes at all levels biological organization. This study examined the potential link between microbiome profile and epigenetic factors.

Language: Английский

---